Janney Montgomery Scott LLC Sells 2,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Janney Montgomery Scott LLC lessened its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 6.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 27,158 shares of the company’s stock after selling 2,000 shares during the period. Janney Montgomery Scott LLC’s holdings in ARS Pharmaceuticals were worth $287,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. nVerses Capital LLC acquired a new position in shares of ARS Pharmaceuticals in the 3rd quarter valued at about $30,000. Quarry LP bought a new stake in ARS Pharmaceuticals in the third quarter worth approximately $174,000. TFG Advisers LLC acquired a new position in ARS Pharmaceuticals in the third quarter valued at approximately $180,000. Stifel Financial Corp acquired a new position in ARS Pharmaceuticals in the third quarter valued at approximately $199,000. Finally, Intech Investment Management LLC bought a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth approximately $239,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on SPRY shares. Raymond James boosted their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Leerink Partners upped their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Finally, Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research report on Monday. They set an “outperform” rating and a $40.00 price objective on the stock. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $28.80.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00. Following the transaction, the director now directly owns 210,346 shares in the company, valued at approximately $2,589,359.26. This trade represents a 19.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Justin Chakma sold 32,814 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $14.00, for a total transaction of $459,396.00. Following the completion of the sale, the insider now owns 203,566 shares of the company’s stock, valued at approximately $2,849,924. The trade was a 13.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 617,102 shares of company stock valued at $7,935,840 over the last three months. Corporate insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Trading Down 1.6 %

SPRY opened at $11.55 on Wednesday. ARS Pharmaceuticals, Inc. has a 1-year low of $6.70 and a 1-year high of $18.51. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -22.65 and a beta of 0.99. The company’s fifty day moving average price is $12.24 and its two-hundred day moving average price is $13.19.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.